Analysis using Olink PEA technology

Combination of clinically significant proteins in plasma defines phenotype and combined biomarker associated with prognosis in critical COVID19 patients


Get access to this webinar, as well as the rest of our categorized library of more than 20 high-quality scientific webinars featuring presentations by leading researchers in their respective fields.

View webinar

COVID-19 is now a common disease, yet peripheral prognostic biomarkers have not been established. However, the identification of a protein signature capable of classifying COVID-19 sub-phenotypes with poor outcomes may enable the discovery of new therapeutic targets.

Using three independent COVID-19 patient cohorts and Olink® Explore 1536, Dr. Matsumoto collaborated with Massachusetts General Hospital to examine the plasma protein profiles of critical COVID-19 patients on Days 1 – 10 spanning hyperacute, acute, and subacute phases. Protein profiles between healthy controls, COVID-19 patients with early recovery, and COVID-19 with late recovery or death were compared.

A 4-protein signature (WFDC2, GDF15, CHI3L1, KRT19) was identified for predicting mortality of critical COVID-19 patients in the hyperacute phase (Day 1), with an area under the curve (AUC) of 0.852 with a sensitivity of 100% and a specificity of 66.3%. This work discovered a clinically useful biomarker signature indicative of prognosis in the hyperacute phase in critical COVID-19 patients.

The webinar covers the following points:

  • 4 proteins were significantly upregulated on Day 1 in critical COVID-19 patients who did not survive compared to critical COVID-19 patients who did survive
  • Co-expression network analysis revealed an enrichment in cell adhesion and immune system process
  • Identification of 4 new clinical survival phenotypes.


Hisatake Matsumoto, Ph.D. Assistant Professor at Osaka University